Skip to Main Content
Skip Nav Destination

Drugging WRN in MSI-H Cancers

April 11, 2024

Abstract: Since the discovery of WRN as a synthetic lethal target in microsatellite instability–high tumor types, the development space for drugs against this enzyme has burgeoned. At least two candidates have entered clinical trials—Novartis’s HRO761 and VVD-214 (Vividion Therapeutics/Roche). There are practical realities to consider, however, including the fact that this patient population already benefits greatly from immune checkpoint blockade.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal